The National Institute for Health and Care Excellence has recommended the use of Semaglutide (Wegovy) for adults with a body mass index (BMI) of at least 35 and one weight-related health condition – such as diabetes or high blood pressure. Using the latest treatments to tackle obesity will contribute to cutting waiting lists by reducing the number of people who suffer from weight-related illnesses.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
